Compare iShares MSCI France ETF (EWQ) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs IDEXX Laboratories, Inc. — how do they compare? iShares MSCI France ETF trades at $47.49, while IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B). The key difference: iShares MSCI France ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| EWQ | IDXX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $766.68 |
52-Week Low | $41.68 | $526.44 |
Market Cap | — | $46.22B |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ (iShares MSCI France ETF) trades at $47.51, down 0.5% on the day, with a bullish technical signal driven by moving averages. The ETF offers exposure to French equities with a 15.3x P/E ratio and favorable PEG of 1.6x according to Seeking Alpha (August 4, 2026). Recent institutional activity shows Allspring Global reduced its position by 26.2% in Q1 2026, while European central bank policy remains a key market driver.
The outlook for EWQ remains positive with French stocks hitting new highs and attractive valuations supporting further upside. Key risks include ECB monetary policy uncertainty amid Middle East tensions and potential production constraints at French nuclear facilities. The concentrated industrial sector exposure (32%) provides growth potential but increases sector-specific vulnerability.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
